Constellation Pharmaceuticals Inc (NASDAQ:CNST) insider Karen Valentine sold 8,550 shares of the business’s stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $35.03, for a total value of $299,506.50. Following the completion of the transaction, the insider now directly owns 14,096 shares in the company, valued at $493,782.88. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.
CNST stock opened at $36.45 on Friday. The stock’s 50 day simple moving average is $38.94 and its 200 day simple moving average is $24.20. Constellation Pharmaceuticals Inc has a fifty-two week low of $6.01 and a fifty-two week high of $59.49. The company has a debt-to-equity ratio of 0.81, a quick ratio of 5.19 and a current ratio of 5.19. The company has a market cap of $1.49 billion, a P/E ratio of -11.61 and a beta of 6.93.
A number of hedge funds have recently bought and sold shares of the stock. Rhumbline Advisers raised its stake in Constellation Pharmaceuticals by 2.4% during the 4th quarter. Rhumbline Advisers now owns 20,331 shares of the company’s stock worth $958,000 after buying an additional 471 shares during the period. Bank of Montreal Can raised its stake in Constellation Pharmaceuticals by 43.0% during the 4th quarter. Bank of Montreal Can now owns 1,937 shares of the company’s stock worth $91,000 after buying an additional 582 shares during the period. Victory Capital Management Inc. raised its stake in Constellation Pharmaceuticals by 43.4% during the 4th quarter. Victory Capital Management Inc. now owns 2,199 shares of the company’s stock worth $73,000 after buying an additional 666 shares during the period. Meeder Asset Management Inc. acquired a new position in Constellation Pharmaceuticals during the 4th quarter worth approximately $36,000. Finally, Citigroup Inc. raised its stake in Constellation Pharmaceuticals by 267.6% during the 4th quarter. Citigroup Inc. now owns 3,099 shares of the company’s stock worth $146,000 after buying an additional 2,256 shares during the period. 49.91% of the stock is currently owned by institutional investors and hedge funds.
About Constellation Pharmaceuticals
Constellation Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib; and CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors.
Recommended Story: What is the price-sales ratio?
Receive News & Ratings for Constellation Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Constellation Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.